Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 129

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos

Tu, Zhuchi, Yang, Weili, Yan, Sen, Yin, An, Gao, Jinquan, Liu, Xudong, Zheng, Yinghui, Zheng, Jiezhao, Li, Zhujun, Yang, Su, Li, Shihua, Guo, Xiangyu, Li, Xiao-Jiang · 2017 · Scientific Reports

Abstract

CRISPR-Cas9 is a powerful new tool for genome editing, but this technique creates mosaic mutations that affect the efficiency and precision of its ability to edit the genome. Reducing mosaic mutations is particularly important for gene therapy and precision genome editing. Although the mechanisms underlying the CRSIPR/Cas9-mediated mosaic mutations remain elusive, the prolonged expression and activity of Cas9 in embryos could contribute to mosaicism in DNA mutations. Here we report that tagging Cas9 with ubiquitin-proteasomal degradation signals can facilitate the degradation of Cas9 in non-human primate embryos. Using embryo-splitting approach, we found that shortening the half-life of Cas9 in fertilized zygotes reduces mosaic mutations and increases its ability to modify genomes in non-human primate embryos. Also, injection of modified Cas9 in one-cell embryos leads to live monkeys with the targeted gene modifications. Our findings suggest that modifying Cas9 activity can be an effective strategy to enhance precision genome editing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep42081

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Targeting Ubiquitin to Cas9 to Increase Its Degradation. (A) Schematic of the Ubiquitin-Cas9 (Ubi-Cas9) vector for the expression of Cas9 with short half-life. Red box indicates the inserted ubiquitin-targeting signal that is tagged to the N-terminus of Cas9. Green box indicates T7 promoter. The C-terminus of Cas9 carries the nuclear localization signal (NLS). (B) Western blot analysis for comparing the half-life of WT-Cas9 and Ubi-Cas9 in transfected HEK293 cells that were treated with 50 μM cycloheximide for different times (0, 4, 8, 12, 24 h) to inhibit protein synthesis. The relative protein levels of WT-Cas9 and Ubi-Cas9 were assessed by densitometric analysis of their bands on western blots, and the value at 0 h was considered 100% (mean ± SEM; n = 3, *p < 0.05; **p < 0.01). Images of full-length gels are seen in supplemental information. (C) Immunocytochemical assays showing the rapid degradation of Ubi-Cas9 in monkey embryos after injection of Ubi-Cas9 mRNA for 24 h or 40 h. WT-Cas9 mRNA injection served as controls. Embryos were stained with anti-Cas9 (green) and DAPI (blue) for nuclear staining. Note that more Ubi-Cas9 is located in the nucleus than the cytoplasm. Scale bar: 20 μm.
Figure 1 Targeting Ubiquitin to Cas9 to Increase Its Degradation. (A) Schematic of the Ubiquitin-Cas9 (Ubi-Cas9) vector for the expression of Cas9 with short half-life. Red box indicates the inserted ubiquitin-targeting signal that is tagged to the N-terminus of Cas9. Green box indicates T7 promoter. The C-terminus of Cas9 carries the nuclear localization signal (NLS). (B) Western blot analysis for comparing the half-life of WT-Cas9 and Ubi-Cas9 in transfected HEK293 cells that were treated with 50 μM cycloheximide for different times (0, 4, 8, 12, 24 h) to inhibit protein synthesis. The relative protein levels of WT-Cas9 and Ubi-Cas9 were assessed by densitometric analysis of their bands on western blots, and the value at 0 h was considered 100% (mean ± SEM; n = 3, *p < 0.05; **p < 0.01). Images of full-length gels are seen in supplemental information. (C) Immunocytochemical assays showing the rapid degradation of Ubi-Cas9 in monkey embryos after injection of Ubi-Cas9 mRNA for 24 h or 40 h. WT-Cas9 mRNA injection served as controls. Embryos were stained with anti-Cas9 (green) and DAPI (blue) for nuclear staining. Note that more Ubi-Cas9 is located in the nucleus than the cytoplasm. Scale bar: 20 μm.CC BY · PubMed Central
Figure 2 Comparison of Pink1 DNA Targeting by Injection of Cas9 mRNA and Cas9 Protein. Identification of Pink1 DNA mutations by T7E1 assay in monkey embryos injected with WT-Cas9 or Ubi-Cas9 mRNA (A) or purified WT-Cas9 protein (B). Representative DNA gel images showing PCR results of single cells from different embryos. Arrow indicates DNA mutation in a single cell from 8-cell embryos. PC is a positive control from embryos injected with Cas9 mRNA and gRNA for Pink1 targeting. M: Molecular markers. (C) Comparison of targeting rates of injected Cas9 protein, WT-Cas9 mRNA, and Ubi-Cas9 mRNA in monkey embryos. The numbers of embryos with targeted gene mutations or embryos containing mutations in all cells are presented. Embryos at the 4- and 8-cell stages were used, and data were obtained from six experiments.
Figure 2 Comparison of Pink1 DNA Targeting by Injection of Cas9 mRNA and Cas9 Protein. Identification of Pink1 DNA mutations by T7E1 assay in monkey embryos injected with WT-Cas9 or Ubi-Cas9 mRNA (A) or purified WT-Cas9 protein (B). Representative DNA gel images showing PCR results of single cells from different embryos. Arrow indicates DNA mutation in a single cell from 8-cell embryos. PC is a positive control from embryos injected with Cas9 mRNA and gRNA for Pink1 targeting. M: Molecular markers. (C) Comparison of targeting rates of injected Cas9 protein, WT-Cas9 mRNA, and Ubi-Cas9 mRNA in monkey embryos. The numbers of embryos with targeted gene mutations or embryos containing mutations in all cells are presented. Embryos at the 4- and 8-cell stages were used, and data were obtained from six experiments.CC BY · PubMed Central
Figure 3 Use of Embryo Splitting to Assess Ubi-Cas9 Targeting Efficiency. (A) Embryo splitting at the 4-cell stage to separate single cells (I, II, III, and IV), which were placed into individual empty zonae pellucidae to further develop to divided embryos that consist of 4 cells (1, 2, 3, and 4). Single cells (1, 2, 3, and 4) were then isolated and used for PCR analysis. (B) Photographs of development of divided monkey embryos: a single cell isolated from 4-cell embryos was transferred into an empty zona pellucida, and then developed to 2- or 4-cell or hatched blastocyst. (C) Hpy188I digestion of the targeted Pink1 gene showing that Ubi-Cas9 mRNA injection yielded a high rate of homogenous mutations in monkey embryos. PCR products of single cells (1, 2, 3, 4) from divided embryos were analyzed. For Hpy188I digestion, red arrows indicate biallelic mutations, whereas green arrows indicate a single allele mutation. Images of full-length gels are seen in supplemental information. (D) In cultured blastomeres that were isolated from embryos injected with Ubi-Cas9 or WT-Cas9, Ubi-Cas9 yielded biallelic mutations in 53% of blastomeres whereas WT-Cas9 generated bialleic mutations in 28% of balstomeres.
Figure 3 Use of Embryo Splitting to Assess Ubi-Cas9 Targeting Efficiency. (A) Embryo splitting at the 4-cell stage to separate single cells (I, II, III, and IV), which were placed into individual empty zonae pellucidae to further develop to divided embryos that consist of 4 cells (1, 2, 3, and 4). Single cells (1, 2, 3, and 4) were then isolated and used for PCR analysis. (B) Photographs of development of divided monkey embryos: a single cell isolated from 4-cell embryos was transferred into an empty zona pellucida, and then developed to 2- or 4-cell or hatched blastocyst. (C) Hpy188I digestion of the targeted Pink1 gene showing that Ubi-Cas9 mRNA injection yielded a high rate of homogenous mutations in monkey embryos. PCR products of single cells (1, 2, 3, 4) from divided embryos were analyzed. For Hpy188I digestion, red arrows indicate biallelic mutations, whereas green arrows indicate a single allele mutation. Images of full-length gels are seen in supplemental information. (D) In cultured blastomeres that were isolated from embryos injected with Ubi-Cas9 or WT-Cas9, Ubi-Cas9 yielded biallelic mutations in 53% of blastomeres whereas WT-Cas9 generated bialleic mutations in 28% of balstomeres.CC BY · PubMed Central
Figure 4 Ubi-Cas9 Targeting of Pink1 Gene. (A) A diagram showing single cell PCR using intact or divided monkey embryos. (B,C) PCR diagnosis of Pink1 exon 2 targeting via Ubi-Cas9 in single cells from intact embryos (B) or divided embryos (C). Gene mutations were diagnosed via digestion of PCR products by Hpy188I. Green arrows indicate one allele mutation, and red arrows indicate biallelic mutations. (D) Quantitative assessment of Ubi-Ca9-mediated homogenous mutations in single cells from intact embryos at the 4–8-cell stage or from divided embryos derived from 4-cell intact embryos. In this graph, 31 intact embryos were used to isolate single cells, and 13 4-cell-stage embryos were divided to single cells for further development to 37 single blastomere embryos; data are presented as mean ± SEM. **p < 0.01. (E) DNA sequencing verified the homogenous mutations in single cells from divided embryos injected with Ubi-Cas9 and gRNA for Pink1 exon 2.
Figure 4 Ubi-Cas9 Targeting of Pink1 Gene. (A) A diagram showing single cell PCR using intact or divided monkey embryos. (B,C) PCR diagnosis of Pink1 exon 2 targeting via Ubi-Cas9 in single cells from intact embryos (B) or divided embryos (C). Gene mutations were diagnosed via digestion of PCR products by Hpy188I. Green arrows indicate one allele mutation, and red arrows indicate biallelic mutations. (D) Quantitative assessment of Ubi-Ca9-mediated homogenous mutations in single cells from intact embryos at the 4–8-cell stage or from divided embryos derived from 4-cell intact embryos. In this graph, 31 intact embryos were used to isolate single cells, and 13 4-cell-stage embryos were divided to single cells for further development to 37 single blastomere embryos; data are presented as mean ± SEM. **p < 0.01. (E) DNA sequencing verified the homogenous mutations in single cells from divided embryos injected with Ubi-Cas9 and gRNA for Pink1 exon 2.CC BY · PubMed Central
Figure 5 Mutations of the ASPM Gene in Monkey Tissues. (A) T7E1 digestion of the targeted ASPM gene in embryos injected with WT-Cas9 or Ubi-Cas9. Green arrows indicate the mutations in single cells isolated from 2-cell or 4-cell embryos. (B) ASPM immunofluorescent staining of 2-cell-stage monkey embryos showing that injection of Ubi-Cas9 mRNA and gRNAs for targeting ASPM can deplete the spindle localization (arrows) of ASPM. Scale bar: 20 μm. (C) Sequence analysis of tissue DNAs from a live monkey indicating mutations in the ASPM gene that was targeted by two gRNAs for exon 3 and exon 10. The numbers of cloned DNA for sequencing and mutated DNA clones are indicated in parentheses (mutated clones/total clones). Targeted sequence regions are indicated in red.
Figure 5 Mutations of the ASPM Gene in Monkey Tissues. (A) T7E1 digestion of the targeted ASPM gene in embryos injected with WT-Cas9 or Ubi-Cas9. Green arrows indicate the mutations in single cells isolated from 2-cell or 4-cell embryos. (B) ASPM immunofluorescent staining of 2-cell-stage monkey embryos showing that injection of Ubi-Cas9 mRNA and gRNAs for targeting ASPM can deplete the spindle localization (arrows) of ASPM. Scale bar: 20 μm. (C) Sequence analysis of tissue DNAs from a live monkey indicating mutations in the ASPM gene that was targeted by two gRNAs for exon 3 and exon 10. The numbers of cloned DNA for sequencing and mutated DNA clones are indicated in parentheses (mutated clones/total clones). Targeted sequence regions are indicated in red.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 24

  1. Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167–170 (2010). · DOI · Paper page
  2. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014). · DOI · Paper page
  3. Yuan, L. et al. CRISPR/Cas9-mediated GJA8 knockout in rabbits recapitulates human congenital cataracts. Sci. Rep. 6, 22024 (2016). · DOI
  4. Zou, Q. et al. Generation of gene-target dogs using CRISPR/Cas9 system. J. Mol. Cell Biol. 7, 580–583 (2015). · DOI
  5. Hai, T., Teng, F., Guo, R., Li, W. & Zhou, Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res. 24, 372–375 (2014). · DOI · Paper page
  6. Whitworth, K. M. et al. Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos. Biol. Reprod. 91, 78 (2014). · DOI · Paper page
  7. Wang, Y. et al. Efficient generation of gene-modified pigs via injection of zygote with Cas9/sgRNA. Sci. Rep. 5, 8256 (2015). · DOI
  8. Chen, Y. et al. Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum. Mol. Genet. 24, 3764–3774 (2015). · DOI · Paper page
  9. Kang, Y. et al. CRISPR/Cas9-mediated Dax1 knockout in the monkey recapitulates human AHC-HH. Hum. Mol. Genet. 24, 7255–7264 (2015). · DOI
  10. Guo, X. & Li, X. J. Targeted genome editing in primate embryos. Cell Res. 25, 767–768 (2015). · DOI · Paper page
  11. Sung, Y. H. et al. Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases. Genome Res 24, 125–131 (2014). · DOI · Paper page
  12. Burger, A. et al. Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein complexes. Development 143, 2025–2037 (2016). · DOI · Paper page
  13. Jao, L.-E., Wente, S. R. & Chen, W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc. Natl. Acad. Sci. USA 110, 16 (2013).
  14. Nico, P. D. et al. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasomedependent proteolysis in living cells. Nat. Biotechol. 18, 438–543 (2000). · DOI · Paper page
  15. Hardy, J. Genetic analysis of pathways to Parkinson disease. Neuron 68, 201–206 (2010). · DOI · Paper page
  16. Hashimoto, M. & Takemoto, T. Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. Sci. Rep. 5, 11315 (2015). · DOI · Paper page
  17. Hashimoto, M., Yamashita, Y. & Takemoto, T. Electroporation of Cas9 protein/sgRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse. Dev. Biol. 418, 1–9 (2016). · DOI · Paper page
  18. Chan, A. W. et al. Clonal propagation of primate offspring by embryo splitting. Science 287, 317–319 (2000). · DOI
  19. Mitalipov, S. M., Yeoman, R. R., Nusser, K. D. & Wolf, D. P. Rhesus monkey embryos produced by nuclear transfer from embryonic blastomeres or somatic cells. Biol. Reprod. 66, 1367–1373 (2002). · doi:10.1095/biolreprod66.5.1367
  20. Zhou, X. et al. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell Mol. Life Sci. 72, 1175–1184 (2015). · DOI · Paper page
  21. Song, J. et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat. Commun. 7, 10548 (2016). · DOI · Paper page
  22. Rajalingam, K. & Dikic, I. SnapShot: Expanding the Ubiquitin Code. Cell 164, 1074–1074 (2016). · DOI
  23. Harding, S. M. & Greenberg, R. A. Choreographing the Double Strand Break Response: Ubiquitin and SUMO Control of Nuclear Architecture. Front. Genet. 7, 103 (2016). · DOI
  24. Bond, J. et al. Protein-truncating mutations in ASPM cause variable reduction in brain size. Am. J. Hum. Genet. 73, 1170–1177 (2003). · DOI · Paper page

Cited by

See all 129

Metadata

Authors
Tu, Z., Yang, W., Yan, S., Yin, A., Gao, J., Liu, X., Zheng, Y., Zheng, J., Li, Z., Yang, S., Li, S., Guo, X., & Li, X.-J.
Venue
Scientific Reports
Published
2017-02-03
Volume
7
Issue
1
ISSN
2045-2322
Cited by
129
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.